Teva: Here’s How We Plan To Solve ‘Litigation Challenges’
Materials ‘Deliberately Not Handed Over Before Closing Remarks,’ Teva Says
After being found liable for helping fuel the opioid epidemic in New York last month, Teva used the J.P. Morgan Healthcare Conference to explain how it intends to go about overturning the verdict.
You may also be interested in...
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.
Teva has delivered the launch of the first generic rival to Narcan naloxone 4mg nasal spray in the US. Sandoz has immediately responded with the introduction of an authorized generic.
Teva CEO Kåre Schultz has spoken at great length and in great detail about Teva’s ability to reach a proposed settlement in the US over allegations the firm helped fuel the opioid epidemic, revealing that a deal may be only 12 months away.